ATE500245T1 - Pyridonamidderivate als fokale adhäsionskinase (fak)-inhibitoren und ihre verwendung zur behandlung von krebs - Google Patents

Pyridonamidderivate als fokale adhäsionskinase (fak)-inhibitoren und ihre verwendung zur behandlung von krebs

Info

Publication number
ATE500245T1
ATE500245T1 AT08785643T AT08785643T ATE500245T1 AT E500245 T1 ATE500245 T1 AT E500245T1 AT 08785643 T AT08785643 T AT 08785643T AT 08785643 T AT08785643 T AT 08785643T AT E500245 T1 ATE500245 T1 AT E500245T1
Authority
AT
Austria
Prior art keywords
cancer
pyridonamide
fak
inhibitors
derivatives
Prior art date
Application number
AT08785643T
Other languages
German (de)
English (en)
Inventor
Guy Georges
Klaus Kaluza
Matthias Koerner
Ulrike Reiff
Stefan Scheiblich
Der Saal Wolfgang Von
Stefan Weigand
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE500245T1 publication Critical patent/ATE500245T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT08785643T 2007-08-22 2008-08-20 Pyridonamidderivate als fokale adhäsionskinase (fak)-inhibitoren und ihre verwendung zur behandlung von krebs ATE500245T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07016399A EP2065380A1 (fr) 2007-08-22 2007-08-22 Dérivés de pyridoneamide comme inhibiteurs de focal adhesion kinase (FAK) et leur utilisation pour le traitement du cancer
PCT/EP2008/006834 WO2009024332A1 (fr) 2007-08-22 2008-08-20 Dérivés de pyridonéamide en tant qu'inhibiteurs de la kinase d'adhésion focale (fak) et leur utilisation pour le traitement du cancer

Publications (1)

Publication Number Publication Date
ATE500245T1 true ATE500245T1 (de) 2011-03-15

Family

ID=38924813

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08785643T ATE500245T1 (de) 2007-08-22 2008-08-20 Pyridonamidderivate als fokale adhäsionskinase (fak)-inhibitoren und ihre verwendung zur behandlung von krebs

Country Status (9)

Country Link
US (1) US20110218199A1 (fr)
EP (2) EP2065380A1 (fr)
JP (1) JP2010536813A (fr)
CN (1) CN101784538A (fr)
AT (1) ATE500245T1 (fr)
CA (1) CA2696197A1 (fr)
DE (1) DE602008005326D1 (fr)
ES (1) ES2360162T3 (fr)
WO (1) WO2009024332A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010140835A2 (fr) * 2009-06-01 2010-12-09 연세대학교 산학협력단 Nouveaux composés de pyridone ou sel pharmaceutiquement acceptable de ceux-ci, méthode de production de ceux-ci, et composition pharmaceutique les contenant dans le traitement du cancer
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
US20130324532A1 (en) 2011-02-17 2013-12-05 Cancer Therapeutics Crc Pty Limited Fak inhibitors
US9174946B2 (en) 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
US10106834B2 (en) 2013-10-09 2018-10-23 The General Hospital Corporation Methods of diagnosing and treating B cell acute lymphoblastic leukemia
MX2016007259A (es) 2013-12-03 2016-08-04 Du Pont Pirrolidinonas como herbicidas.
US11589583B2 (en) 2013-12-03 2023-02-28 Fmc Corporation Pyrrolidinones herbicides
US9944602B2 (en) 2014-07-02 2018-04-17 E. I. Du Pont De Nemours And Company Piperidinone herbicides
EP3230264B1 (fr) 2014-12-08 2019-09-11 FMC Corporation 3-oxo-3-(arylamino)propanoates, leur procédé de préparation et leur utilisation dans la préparation de pyrrolidinones
EP3280709B1 (fr) 2015-04-10 2021-05-26 FMC Corporation Amides cycliques susbtitués utilisés comme herbicides
CN107531658B (zh) 2015-04-27 2021-07-27 Fmc公司 作为除草剂的丁内酯
PL3294743T3 (pl) 2015-05-12 2020-03-31 Fmc Corporation Podstawione arylem związki bicykliczne jako środki chwastobójcze
WO2016196019A1 (fr) * 2015-05-29 2016-12-08 E I Du Pont De Nemours And Company Amides cycliques substitués utilisés comme herbicides
CN107709310B (zh) 2015-06-02 2021-09-24 Fmc公司 取代的环酰胺及其作为除草剂的用途
PT3733187T (pt) 2015-07-21 2024-11-08 Turning Point Therapeutics Inc Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro
CN108137512B (zh) 2015-07-31 2022-05-31 Fmc公司 用作除草剂的环状n-酰胺化合物
CA3047724A1 (fr) 2016-12-21 2018-06-28 Fmc Corporation Herbicides a base de nitrone
WO2018175231A1 (fr) 2017-03-21 2018-09-27 Fmc Corporation Mélange herbicide, composition et procédé
CA3057297A1 (fr) 2017-03-21 2018-09-27 Fmc Corporation Pyrrolidinones et procede pour les preparer
AR111839A1 (es) 2017-05-30 2019-08-21 Fmc Corp Lactamas 3-sustituidas herbicidas
AR111967A1 (es) 2017-05-30 2019-09-04 Fmc Corp Amidas herbicidas
CN120513245A (zh) 2022-11-15 2025-08-19 克拉德夫制药有限公司 造血前驱细胞激酶1的吡啶酮及嘧啶酮抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
GEP20053660B (en) * 2001-03-28 2005-11-10 Bristol Myers Squibb Co Novel Tyrosine Kinase Inhibitors
US7189716B2 (en) * 2003-01-03 2007-03-13 Bristol-Myers Squibb Company Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
CN101784538A (zh) 2010-07-21
JP2010536813A (ja) 2010-12-02
CA2696197A1 (fr) 2009-02-26
EP2065380A1 (fr) 2009-06-03
ES2360162T3 (es) 2011-06-01
DE602008005326D1 (de) 2011-04-14
US20110218199A1 (en) 2011-09-08
EP2190834B1 (fr) 2011-03-02
EP2190834A1 (fr) 2010-06-02
WO2009024332A1 (fr) 2009-02-26

Similar Documents

Publication Publication Date Title
ATE500245T1 (de) Pyridonamidderivate als fokale adhäsionskinase (fak)-inhibitoren und ihre verwendung zur behandlung von krebs
MX2009002010A (es) Derivados de heteroarilo como inhibidores de la proteina cinasa.
WO2006066913A3 (fr) Derives benzamides, leur fabrication et leur utilisation comme agents pharmaceutiques
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
TW200730502A (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
ATE400570T1 (de) 2,4,6-trisubstituierte pyrimidine als inhibitoren von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs
WO2009121535A3 (fr) Composés antiprolifératifs et leurs utilisations thérapeutiques
WO2006066914A3 (fr) Derives carbamates heterocycliques, leur fabrication et leur utilisation comme agents pharmaceutiques
MX2007003104A (es) Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a.
NO20061415L (no) Kinazolinderivater
ATE439361T1 (de) 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
ATE499372T1 (de) Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
MX2008011769A (es) Derivados de ftalazinona pirazol, su fabricacion y uso como agentes farmaceuticos.
DE602007010038D1 (de) Pyrimidylderivate als proteinkinaseinhibitoren
TW200719899A (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
TW200505913A (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents
TW200602329A (en) Novel diazine derivatives, their manufacture and use as pharmaceutical agents
TW200720239A (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties